Emergent BioSolutions (EBS) Tops Q1 EPS by 22c

Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of $0.71, $0.22 better than the analyst estimate of $0.49. Revenue for the quarter came in at $222.2 million versus the consensus estimate of $279 million.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.

You May Also Be Interested In

• Netflix climbs following Ackman stake, up 1.8%
• McGraw Hill (MH) Tops Q2 EPS by 11c, Beats on Revenue; Offers FY26 Guidance
• Fermi Inc. (FRMI) Reports Q2 Loss of $0.04